BioNTech (NASDAQ:BNTX) is the developer of the highly effective corona vaccine BNT162b2, which is known in Europe under the name Comirnaty. The focus of the Mainz-based company, which has been listed on the U.S. Nasdaq stock exchange since the end of 2019, is research into mRNA-based drugs.
It was the first company in the world to develop an mRNA-based drug for intramuscular administration; to bring customizable mRNA-based cancer immunotherapy into clinical trials; and to establish its manufacturing process for such a product candidate.
The company’s mRNA drugs can be used as individualized cancer immunotherapies; infectious disease vaccines; and protein replacement therapies for rare diseases. In addition, the biotech company is active in research into programmable cell therapies. BioNTech is developing novel antibodies and small molecule immunomodulators as treatment options for cancer.
A Success Story: The Corona Vaccine Comirnaty
The BioNTech success story of recent months is based on the successful development of the Corona vaccine BNT162b2, which is marketed in Europe under the name Comirnaty (otherwise also known as Tozinameran).
The vaccine shows very high efficacy after two vaccinations. Patients also better tolerate this vaccine than others developed by manufacturers against the Covid-19 virus (I took my first dose very well).
For this reason, the BioNTech vaccine is considered the first choice by patients and physicians. Moreover, the mega-success has led to billions of vaccine doses being distributed worldwide in collaboration with pharmaceutical giant Pfizer. And billions of more doses have already been ordered. That has created a lot of cash flow. It’s great news.
BioNTech can now use its “war chest,” which is swelling thanks to the high sales proceeds, opening more sites, investing in research and development of other drugs and therapies and making acquisitions.
For example, the Mainz-based group recently bought the cell therapy platform of the U.S. company Kite.
BioNTech intends to expand its cancer pipeline as a result. Specifically, the acquired technology will be used to develop individual immunotherapies that stimulate a patient’s immune system to recognize and attack tumors.
In addition to the technology platform, BioNTech is also purchasing a manufacturing facility in the U.S. from Kite as a research, development, and manufacturing site for the clinical development of cell therapies.
Sales and earnings explosion in the first quarter of 2021
BioNTech shares have been on an impressive upward trend since the IPO in 2019 and are currently achieving one all-time high after the next. As a result, the interest of institutional investors in the share is enormous. In the last six quarters, the share has been steadily added to large investors such as funds and investment houses.